Key Insights:
- Dr. Jessica Allegretti discusses two FDA-approved fecal microbiota transplantation (FMT) products—Rebyota and VOWST—that offer different administration methods to prevent recurrent Clostridium difficile infections (CDI).
- Accessing these products can be complicated due to insurance coverage issues, despite their proven safety and effectiveness in preventing recurrent CDI.
- Gastroenterologists must consider the patient’s ability to tolerate different administration routes and the speed of product availability, balancing FDA approval status and patient preferences.
The availability of multiple FMT products provides flexibility in managing recurrent CDI, but challenges in accessibility and patient-specific considerations remain crucial.